What this sample shows
This is a simulated Commercial Readiness Assessment© for PhenoVista Biosciences, a founder-led high-content imaging and cell-based assay services company. It illustrates the output of the full CRA diagnostic: a 0–100 Commercial Readiness Index, a pillar heatmap, a prioritized 90-day roadmap, and a leadership-alignment view.
The inputs are illustrative, but the structure and interpretation are representative of what a new ownership group receives after a four-week assessment.
Key findings at a glance
PhenoVista scores 39 out of 100 — squarely in the Emerging Commercial Structure band. Customer experience and retention are strengths; forecast integrity, sales execution, and market prioritization are the highest-impact gaps.
- **CRI© Composite:** 39 / 100 — Emerging
- **Top gap:** Predictable Revenue & Forecast Integrity (9.3 point lift available)
- **Second gap:** Disciplined Sales Execution (5.9 point lift)
- **Third gap:** Market Strategy & Segmentation (5.3 point lift)
- **90-day focus:** Standardize the core — forecast cadence, MEDDICC deal qualification, and ICP re-segmentation
What comes with the report
The downloadable report walks through the full assessment output, including:
- How the CRA works and the COS framework it measures against
- Executive summary with CRI score, maturity band, and 90-day focus
- Pillar snapshot and top-priority gap analysis
- Leadership alignment view — where the leadership team sees the same issue differently
- What's working, where to focus, and a prioritized 90-day roadmap
- Recommended next steps and the bottom line for an owner
Download the sample
Use the button above to download the full simulated report. It is a useful reference for boards, investors, and leadership teams who want to see what a fact-based commercial baseline looks like before running the assessment.